ClinicalTrials.gg
RecruitingNCT06581315Updated Sep 3, 2024

Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma

An interventional study of Donafenib in Hepatocellular Carcinoma and Adjuvant Therapy, sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-09-03.

Sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing donafenib in Carcinoma, Hepatocellular — 9 open to participants now, 9 under way, none of them phase 3. donafenib · Carcinoma, Hepatocellular.

Planned enrollment
Largest of 18
204 · median 32
Started
2024
with 6 others
No phase
3 of 18
3 open now
Registered
14th of 18
by date
Lead sponsor
3 of 18
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Among the 18 studies testing donafenib in Carcinoma, Hepatocellular, this one has the largest planned enrollment, is one of 7 that started in 2024, is one of 3 with no phase, and was the 14th registered.

Carcinoma, Hepatocellular

3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

9 of the 18 studies testing donafenib in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About donafenib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing donafenib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of donafenib as adjuvant therapy for postoperative patients with high-risk recurrent Hepatocellular Carcinoma. This is a multicenter, randomized controlled study.

03

Conditions studied

  • Hepatocellular Carcinoma
  • Adjuvant Therapy

Keywords

  • Hepatocellular Carcinoma
  • Adjuvant Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants underwent radical resection of hepatocellular carcinoma 4 weeks before randomization
  • High Risk of recurrence as assessed by tumor characteristics
  • Without any anti-tumor therapy before surgery, except preoperative TACE therapy, traditional Chinese medicine therapy and interferon therapy
  • Class A statu
  • Performance Status of 0 or 1
  • CT/MR confirmed no recurrence or at ≥4 weeks after surgery
  • Expected survival time of no less than 3 months

Exclusion criteria

Exclusion Criteria:

  • Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC
  • Evidence of residual or a history of spontaneous tumor rupture
  • Recurrent HCC
  • Prior received Liver transplantation
  • Prior anti tumor therapy for treatment of HCC (including sorafenib or any other molecular therapy, antibody and other immunotherapies, FOLFOX systemic chemotherapy) is excluded
  • AFP does not return to normal 4 weeks after operation
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
204 participants (estimated)

Study arms

  • Experimental
    Arm A (Donafenib)

    Participants will receive Donafenib treatment until disease recurrence or unacceptable toxicity or up to 1 years.

    Drug: Donafenib

  • No intervention
    Arm B (active surveillance)

    Active surveillance of participants.

Interventions

  • Donafenib 100 mg twice daily (BID)

    Also known as: Zepsun

06

What researchers measure

Primary outcomes

  1. One year recurrence-free survival (RFS) rate

    The proportion from randomization to 1 year without recurrence.

    Time frame: 1 year

Secondary outcomes

  1. Recurrence-Free Survival (RFS )

    The time from randomization to disease recurrence, or death from any cause (whichever occurs first).

    Time frame: 6 years

  2. Recurrence-Free Survival rate (RFS rate)

    The proportion from randomization to 2 years, 3 years or 5 years without recurrence.

    Time frame: 5 years

  3. Overall Survival (OS)

    The time from randomization to death from any cause.

    Time frame: 6 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Aug 2027, 36 months later.

Of 361 non-industry interventional studies with no phase under Carcinoma, Hepatocellular, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 36 months is below that.

Counting every sponsor, half of 385 studies reached it within 47 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartEst.
Aug 28, 2024
Primary completionEst.
Aug 30, 2027
CompletionEst.
Aug 30, 2032
Last update
Sep 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06581315
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Aug 28, 2024 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Aug 30, 2032 (estimated)
Last update
Sep 3, 2024

Study contacts

Changzhen Shang, MD
Contact
shchzh2@mail.sysu.edu.cn
+86-20-3407 0701
Changzhen Shang, MD
principal investigator · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donafenib

Start the discussion